Daping Hospital and the Research Institute of Surgery of the Third Military Medical University: Lung Neoplasms trials
The registry lists 11 Lung Neoplasms studies with Daping Hospital and the Research Institute of Surgery of the Third Military Medical University as lead sponsor. 4 are open to participants now and 0 have results posted.
Phase 2 3Phase 3 1Phase 4 1No phase 6(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Efficacy and Safety of Serplulimab With Chemotherapy and Aspirin in Untreated Extensive-Stage Small Cell Lung CancerNot yet recruitingNCT06554535Phase 2
- Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLCNot yet recruitingNCT06436144Phase 2
- To Explore the Effect of Immune-induced Stereotactic Body Radiotherapy (SBRT) on Reversing Immunoresistance in Stage IIIc/IV Non-small Cell Lung Cancer (NSCLC)Not yet recruitingNCT06154967Not applicable
- The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLCNot yet recruitingNCT06117644
- PPIO-006 Primary Tumor Resection for IVa NSCLCCompletedNCT06232967
- Effect of Muscle and Skin Fixation of Thoracic Drainage Tube on Postoperative PainStatus unknownNCT05202249Not applicable
- Modified Versus Traditional Thoracic Drainage After Thoracoscopic SurgeryStatus unknownNCT04309955Not applicable
- Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLCCompletedNCT03543683Phase 2
- Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC)Status unknownNCT03532698
- Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung CancerStatus unknownNCT02480634Phase 4
- Phase Ⅲ Trial of WBRT Versus Erlotinib Concurrent Whole-brain Radiation Therapy as first-line Treatment for Patients With Multiple Brain Metastases From Non-small-cell Lung Cancer(ENTER): a Multicentre, Open-label, Randomised StudyCompletedNCT01887795Phase 3